XNK Therapeutics appoints Hans Ericson as CFO

May 5, 2020

XNK Therapeutics AB (“XNK”) today announced the appointment of Hans Ericson as Chief Financial Officer

Hans Ericson is a senior finance professional with more than 20 years’ experience in international business and public traded companies. He has had a number of leading positions including at Ericsson and Elekta. Hans has also worked as a consultant in various areas, from start-ups to large research organizations, including Research Institute of Sweden (RISE).

“I am very pleased to have Hans Ericson joining the XNK team,” says Johan Liwing, CEO of XNK Therapeutics. “He brings solid experience to the company that will help us take XNK to the next level.”

For more information, please contact:
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
E-mail: johan.liwing@xnktherapeutics.com

About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

About XNK Therapeutics technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen. The assets of XNK Therapeutics are protected by patents in the US, Europe and certain other jurisdictions. Additional patent applications have been filed.

XNK Therapeutics appoints Johan Liwing as CEO

April 1, 2020

XNK Therapeutics AB (“XNK”) today announced its appointment of Johan Liwing as CEO of the company and prepares for the next phase of development of its technology platform and leading drug candidate.

Liwing, has over 15 years’ experience from leading positions within the life science industry in Sweden as well as internationally. During his 13 years at Janssen, a subsidiary of Johnson & Johnson, he held various positions in health economics, sales & marketing as well as observational research with increased responsibilities. In his last position at Janssen, as global senior director, he was responsible for developing the use of observational data.

After eight years as CEO of XNK, Karin Mellström will step down and remain as Senior Adviser.

“I am very happy to be part of XNK Therapeutics and I look forward to realizing the great potential within the company,” said Johan Liwing, CEO of XNK Therapeutics.  I strongly believe that XNK Therapeutics technology platform and the leading investigational drug candidate have the ideal properties for being a critical component in tomorrow’s cancer strategies.”

“We are fortunate to have Johan step in and lead XNK Therapeutics at this critical phase in the development of our autologous NK cell therapy,” said Lena Degling Wikingsson, Chairman of XNK Therapeutics. “Johan’s strategic, clinical and marketing experiences from global pharma positions and significant network will bring important knowledge and strength to the company. At the same time, I would like to give my sincere appreciation to Karin for her great efforts to lead the company to this phase.”

During Mellström’s years as CEO the company achieved several key milestones. The company secured critical patents for its technology platform and developed its first investigational drug candidate. A First-in-Human phase I/II clinical study was conducted for the leading indication, a consolidation treatment after high dose autologous stem cell transplantation in patients with multiple myeloma. The leading drug candidate was also granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma in Europe and XNK is planning to advance the clinical development and reach the market via accelerated/conditional approval. An ODD application was also submitted to the U.S. Food and Drug Administration.

For more information, please contact:
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
E-mail: johan.liwing@xnktherapeutics.com

About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

About XNK Therapeutics’s technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen. The assets of XNK Therapeutics are protected by patents in the US, Europe and certain other jurisdictions. Additional patent applications have been filed.

XNK Therapeutics joins Vinnova’s NextGenNK competence center

Januari 31, 2020

XNK Therapeutics AB (“XNK”) today announced it joined Sweden’s Innovation Agency’s NextGenNK competence center for the development of next-generation natural killer (NK) cell-based cancer immunotherapies

Vinnova, Sweden’s innovation agency, is making a significant investment in NextGenNK, where universities and companies will conduct world-class research and innovation in important areas for Sweden while contributing to its global sustainability goals. NextGenNK has received commitments from a consortium of key opinion leaders and experts from academia and the biotech industry to collectively collaborate to create a recognized world-class research environment in the field of NK cell-based immunotherapy targeting cancers.

XNK will work within this competence center to conduct exploratory analyses of the company’s lead investigational product and patient material. The competence center partners have a mutual interest in achieving research results regarding exploratory and immunoinformatic analyses of clinical material. NextGenNK will also support XNK with advanced phenotypic characterization and functionality testing of the Company’s leading drug candidate. The collaboration will extend over five years.

NextGenNK is led by its Director, Hans-Gustaf Ljunggren, M.D., Ph.D., Professor at the Department of Medicine at KI, former Dean of Research at KI, former Director of the Center for Infectious Medicine at KI, Board Member of XNK Therapeutics, and member of the Nobel Assembly at KI.

“We are grateful to Vinnova for recognizing the potential global impact on human health by establishing NextGenNK,” stated Dr. Ljunggren. “We propose to develop a precision-medicine strategy to direct NK cells to their cancer targets and to optimally stimulate NK cell activity in the body. By assembling leading scientists and clinicians, including those who have played key roles over the past four decades of NK cell innovation, this collaboration and discovery-network are expected to generate outcomes that go far beyond the capability of any individual partner.”

“I am excited that XNK can be part of this competence center building on the research that has been part of KI since the discovery of NK cells in the 1970s,” said Johan Liwing, CEO of XNK Therapeutics. “XNK is one of the pioneering companies within the Swedish Advanced Therapy Medicinal Products (ATMP) landscape, and we are happy to contribute and strengthen Sweden’s position in the international field of NK cell research. Furthermore, this collaboration will be critical for the clinical development of our leading drug candidate.”

For more information, please contact:
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
E-mail: johan.liwing@xnktherapeutics.com

About XNK Therapeutics AB
XNK Therapeutics is a clinical-stage immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

About XNK Therapeutics’ technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for the development of NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen. The assets of XNK Therapeutics are protected by patents in the US, Europe, and certain other jurisdictions. Additional patent applications have been filed.

XNK patent for expansion of NK cells validated in 18 European countries

November 1, 2019

XNK Therapeutics AB (“XNK”) today announced its European patent for the process of expanding NK cells has been validated in 18 countries across the region.

The patent covers XNK’s production methods for expansion and activation of a patient’s own NK cells, which are later given back to the patient to treat cancer. The patent is valid until 2030.

“Receiving a patent for the way we produce the NK cells for our treatments and validating it broadly across Europe is a great step forward for us as we continue to prepare XNK for the future,” said Karin Mellström, CEO of XNK Therapeutics.

For more information, please contact:
Karin Mellström, CEO, XNK Therapeutics
E-mail: info@xnktherapeutics.com

About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

About XNK Therapeutics’ technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen.

XNK Therapeutics patent for expansion of NK cells granted in Japan

August 1, 2019

XNK Therapeutics AB (“XNK”) today announced that Japan has granted the company a patent for its process of expanding NK cells

The patent covers XNK’s production methods for expansion and activation of a patient’s own NK cells, which are later given back to the patient to treat cancer. The patent is valid until 2030.

“We are happy to receive a patent in Japan for the way we produce the NK cells for our treatments. XNK works actively with patent applications and protection not only in the US and Europe, but also in a number of other major markets,” said Karin Mellström, CEO of XNK Therapeutics.

For more information, please contact:
Karin Mellström, CEO, XNK Therapeutics
E-mail: info@xnktherapeutics.com

About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

About XNK Therapeutics’ technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen.

XNK patent for expansion of NK cells granted in Europe

June 1, 2019

XNK Therapeutics AB (“XNK”) today announced it has received a European patent for the process of expanding NK cells.

The patent covers XNK’s production methods for large scale expansion and activation of a patient’s own NK cells, which are later given back to the patient to treat cancer. The patent is valid until 2030. The process in Europe now continues with validation of the patent in selected European countries.

For more information, please contact:
Karin Mellström, CEO, XNK Therapeutics
E-mail: info@xnktherapeutics.com

About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

About XNK Therapeutics’ technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen.

XNK Therapeutics granted SEK1m by Sweden’s Vinnova

November 22, 2018

XNK Therapeutics AB (“XNK”) today announced that Vinnova, a Swedish government-sponsored innovation agency, has granted XNK SEK1 million to upscale production of CellProtect.

“We are extremely pleased to gain the support of Vinnova as we develop our therapy platform CellProtect for future clinical trials,” said Karin Mellström, CEO of XNK Therapeutics. “The grant funding will go a long way in taking our innovative technology to the next level.”

For more information, please contact:
Karin Mellström, CEO, XNK Therapeutics
E-mail: info@xnktherapeutics.com

About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

About XNK Therapeutics’ technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen.

XNK Therapeutics’ patent for expansion of NK cells granted in Korea

November 12, 2018

XNK Therapeutics AB (“XNK”) today announced that Korea has granted the company a patent for its process of expanding NK cells.

The patent covers XNK’s production methods for expansion and activation of a patient’s own NK cells, which are later given back to the patient to treat cancer. The patent is valid until 2030.

“We are happy to receive a patent in Korea for the way we produce the NK cells for our treatments. XNK works actively with patent applications and protection not only in the US and Europe, but also in a number of other major markets,” said Karin Mellström, CEO of XNK Therapeutics.

For more information, please contact:
Karin Mellström, CEO, XNK Therapeutics
E-mail: info@xnktherapeutics.com

About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

About XNK Therapeutics’ technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen.

XNK Therapeutics becomes a partner in Swelife’s health economics project

November 12, 2018

XNK Therapeutics AB (“XNK”) today announced it has become a partner in Swelife’s health economics project on Advanced Therapy Medicinal Products (ATMP).

The partnership allows the company to develop its technology within the Swelife ATMP organization. The main objective of the project is to stimulate and promote growth within the Swedish ATMP sector by nationally developing associated skills in process development and commercial challenges and making them available on a broader scale.

Swelife supports collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health. It is a strategic innovation program, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the program’s partners.

For more information, please contact:
Karin Mellström, CEO, XNK Therapeutics
E-mail: info@xnktherapeutics.com

About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

About XNK Therapeutics’ technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen.

Agneta Edberg appointed to board of XNK Therapeutics

May 7, 2018

XNK Therapeutics AB (“XNK”) today announced it strengthened its organization by appointing Agneta Edberg to the board of directors.

Agneta Edberg has over 25 years’ experience from leading positions in the life sciences industry. She has been CEO at Mylan Nordic AB and the Swedish Pharmaceutical Insurance and has held leading positions within Pfizer, Bactiguard and Cilag (Johnson & Johnson).

Edberg has extensive experience from several board assignments among other as chairman of the board of Immunicum AB, an immuno-oncology company listed on Nasdaq Stockholm and chairman of the board of Idogen AB, a company engineering immune-tolerance based on dendritic cells. She also participates on the board of the Vinnova project CAMP, Centre for Advanced Medical Products, a public private partnership consortium to accelerate new breakthrough ATMP therapies to patients.

For more information, please contact:
Karin Mellström, CEO, XNK Therapeutics
E-mail: info@xnktherapeutics.com

About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

About XNK Therapeutics’ technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen.